Progress in Congenital Cardiac Care for Newborns and Infants: The Emerging Role of "Off-label" Medications

Newborn and Infant Nursing Reviews

Volumn 9, Issue 1, 2009, Pages 18-30

  Torres, Marilyn ^a   Nieves, Jo Ann ^a  

^a MIAMI CHILDREN'S HOSPITAL   (United States)

Author keywords

"Off label" medications; Cardiac; Congenital heart disease; Low cardiac output; Newborns and infants

Indexed keywords

EID: 59449109899     PISSN: 15273369     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.nainr.2008.12.006     Document Type: Article

References (75)

1. Pierpont M.A., Basson C.T., Benson D.W., et al. Genetic basis for congenital heart defects: current knowledge. A scientific statement from the American Heart Association Congenital Cardiac Defects Committee, Council on Cardiovascular Disease in the Young: Endorsed by the American Academy of Pediatrics. Circulation 115 (2007) 3015-3038
2. Botto L.D., and Goldmuntz E. Epidemiology and prevention of congenital heart disease. In: Allen H.D., Driscoll D.J., Feltes T.F., and Shaddy R.E. (Eds). Moss and Adams' heart disease in infants, children, and adolescents including the fetus and young adult. 7th ed. (2008), Lippincott Williams & Wilkins, Philadelphia 524-544
3. Society of thoracic surgeons executive summary. Congenital heart surgery database. http://www.sts.org/sections/stsnationaldatabase/publications/executive/a rticle.html [accessed 10/30/2008]
4. Wernovsky G., Chang A.C., Wessel D.L., and Ravishankar C. Cardiac intensive care. In: Allen H.D., Driscoll D.J., Feltes T.F., and Shaddy R.E. (Eds). Moss and Adams' heart disease in infants, children, and adolescent including the fetus and young adult. 7th ed. (2008), Lippincott Williams & Wilkins, Philadelphia 448-480
5. Costello J.M., and Almodovar M.C. Emergency card for infants and children with acute cardiac disease. Clin Pediatr Emerg Med 8 (2007) [MD Consult]
6. Galantowicz M., Cheatham J.P., Phillips A., et al. Hybrid approach for hypoplastic left heart syndrome: intermediate results after the learning curve. Ann Thorac Surg 85 (2008) 2063-2070
7. Daniels C.J. The adolescent and adult a with congenital heart disease. In: Allen H.D., Driscoll D.J., Feltes T.F., and Shaddy R.E. (Eds). Moss and Adams' heart disease in infants, children, and adolescents including the fetus and young adult. 7th ed. (2008), Lippincott Williams & Wilkins, Philadelphia 1370-1396
8. Shah S.S., Hall M., Goodman D.M., et al. Off label drug use in hospitalized children. Arch Pediatr Adolesc Med 161 (2007) 282-290
9. Hoffman T.M., Wernovsky G., Atz A.M., et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 107 (2003) 996-1002
10. Wernovsky G., Wypij D., Jonas R.A., et al. Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants: a comparison of low-flow cardiopulmonary bypass and circulatory arrest. Circulation 92 (1995) 2226-2235
11. Tourneux P., Thameur R., Abdel Gérard K., and Laurent S. Noradrenaline for management of septic shock refractory to fluid and dopamine or dobutamine in full-term newborn infants. Acta Paediatr (2008) 1-4
12. Ward R.M., and Lugo R.A. Cardiovascular drugs for the newborn. Clin Perinatol 32 (2005) 979-997
13. Strodtbeck F., and Theorll C. Drug therapy for infants with cardiac disease. Newborn Infant Nurs Rev 60 (2002) 60-73
14. May L.E. Pediatric heart surgery: a ready reference for professionals. 4th ed. (2008), maxiSHARE, Milwaukee (Wis)
15. In: Allen H.D., Driscoll D.J., Feltes T.F., and Shaddy R.E. (Eds). Moss and Adams' heart disease in infants, children, and adolescents including the fetus and young adult. 7th ed. (2008), Lippincott Williams & Wilkins, Philadelphia
16. Chang A.C., Atz A.M., Andrew M., Wernovsky G., Redmond B., and Wessel D. Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery. Crit Care Med 23 (1995) 1907-1914
17. Barton P., Garcia J., Kouatli A., et al. Hemodynamic effects of IV milrinone lactate in pediatric patients with septic shock: a prospective, double-blinded, randomized, placebo-controlled, interventional study. Chest 109 (1996) 1302-1312
18. Henderson L., Tenero D., Baidoo C., et al. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. Am J Cardiol 98 Suppl (2006) 17L-26L
19. Moser M., and Frishman W. Results of therapy with carvedilol, a betablocker vasodilator with antioxidant properties, in hypertensive patients. Am J Hypertens 11 (1998) 15-22
20. Keating G.M., and Jarvis B. Carvedilol: a review of its use in chronic heart failure. Drugs 63 (2003) 1697-1741
21. Bristow M., Roden R., Lowes B., Gilbert E., and Eichhorn E. The role of third-generation beta-blocking agents in chronic heart failure. Clin Cardiol 21 Suppl (1998) 1-3
22. Bonet S., Agusti A., Arnau J.M., et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients' characteristics: a meta-analysis of clinical trials. Arch Intern Med 160 (2000) 621
23. Bruns L., and Canter C. Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure?. Paediatr Drugs 4 (2002) 771-778
24. Shaddy R.E., Boucek M.M., Hsu D.T., et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 298 (2007) 1171-1179
25. Buck M. Use of carvedilol in children with cardiac failure. Pediatr Pharm (2005)
26. Costello J. Initial experience with fenoldopam after cardiac surgery in neonates with an insufficient response to conventional diuretics. Pediatr Crit Care Med 7 (2006) 28-33
27. Moffett B., and Orellana R. Renal effects of fenoldopam in critically ill pediatric patients. Pediatr Crit Care Med 9 (2008) 403-406
28. Gomez H.J., Cirillo V.J., and Jones K.H. The clinical pharmacology of enalapril. J Hypertens Suppl 1 (1983) 65-70
29. Hardman JG, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edition.
30. Sweet C.S., Gaul S.L., Reitz P.M., Blaine E.H., and Ribeiro L.T. Mechanism of action of enalapril in experimental hypertension and acute left ventricular failure. J Hypertens Suppl 1 (1983) 53-63
31. Calabro R., Pisacane C., Pacileo G., and Russo M. Hemodynamic effects of a single oral dose of enalapril among children with asymptomatic chronic mitral regurgitation. Am Heart J 138 (1999) 955-961
32. Seguchi M., Nakazawa M., and Momma K. Effect of enalapril on infants and children with congestive heart failure. Cardiol Young 2 (1992) 14-19
33. Hoffman T.M., and Welty S.E. Physiology of the preterm and term infant. In: Allen H.D., Driscoll D.J., Feltes T.F., and Shaddy R.E. (Eds). Moss and Adams' heart disease in infants, children, and adolescents including the fetus and young adult. 7th ed. (2008), Lippincott Williams & Wilkins, Philadelphia 440-447
34. Wessel D.L., and Laussen P.C. Intensive care unit. In: Keane J.F., Lock J.E., and Fyler D.C. (Eds). Nadas' pediatric cardiology. 2nd ed. (2006), Elsevier, Philadelphia
35. Nieves J. Pulmonary hypertension: nursing plan of care. In: Verger J.T., and Lebet L.M. (Eds). American Association of Critical Care Nurses procedural manual for pediatric acute and critical care (2008), Saunders, Elsevier, St. Louis 523-529
36. Zamanian R.T., Haddad F., Doyle R.L., and Weinacker A.B. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med 35 (2007) 2037-2050
37. Humbert M., Sitbon O., and Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 351 (2004) 1425-1436
38. Fineman J.R., Heymann M.A., and Morin III F.C. Fetal and postnatal circulations: pulmonary and persistent pulmonary hypertension of the newborn. In: Allen H.D., Clark E.B., Gutgesell H.P., and Driscoll D.J. (Eds). Moss & Adams heart disease in infants, children, and adolescents including the fetus and young adult. 6th ed. (2001), Lippincott Williams & Wilkins, Philadelphia 41-52
39. Gamillscheg A., Zobel G., Urlesberger B., et al. Inhaled nitric oxide in patients with critical pulmonary perfusion after Fontan-type procedures and bidirectional Glenn anastomosis. J Thorac Cardiovasc Surg 113 (1997) 435-442
40. Miller O.I., Tang S.F., Keech A., Pigott N.B., Beller E., and Celemajer D.S. Inhaled nitric oxide and prevention pulmonary hypertension after congenital heart surgery: a randomized double-blind study. Lancet 356 (2000) 1464-1469
41. Roberts J.D., Lang P., Bigatello L.M., Vlahakes G.J., and Zapol W.M. Inhaled nitric oxide in congenital heart disease. Circulation 87 (1993) 447-453
42. Miller O.I., Celermajer D.S., Deanfield J.E., and Macrae D.J. Very-low-dose inhaled nitric oxide: a selective pulmonary vasodilator after operations for congenital heart disease. J Thorac Cardiovasc Surg 108 (1994) 487-494
43. Khazin V., Kaufman Y., Zabeeda D., et al. Milrinone and nitric oxide: combined effect on pulmonary artery pressures after cardiopulmonary bypass in children. J Cardiothorac Vasc Anesth 18 (2004) 156-159
44. Knight D. Newborn drug services: nitric oxide (2008). http://www.akhealth.co.nz/newborn/DrugProtocols/NitricOxidePharmacology. htm
45. Atz A.M. Rebound pulmonary hypertension after inhalation of nitric oxide. Ann Thorac Surg 62 (1996) 1759-1764
46. Schulze-Neick I., Werner H., Penny D.J., Alexi-Meskishvili V., and Lange P.E. Acute ventilatory restriction in children after weaning off inhaled nitric oxide: relation to rebound pulmonary hypertension. Intensive Care Med 25 (1999) 76-80
47. Poongundran M., Theilen U., Warwick W., et al. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 174 (2006) 1042-1047
48. Atz A.M., Lefler A.K., Fairbrother D.L., et al. Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg 124 (2002) 628-629
49. Atz A.M., and Wessel D.L. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 91 (1999) 307-310
50. Raja S.G., Danton M.D., MacArthur K.J., and Pollock J.C. Effects of escalating doses of sildenafil on hemodynamics and gas exchange in children with pulmonary hypertension and congenital cardiac defects. J Cardiothorac Vasc Anesth 21 (2007) 203-207
51. Galie N., Beghetti M., Gatzoulis M.A., et al. Bosentan therapy in patients with Eisenmenger syndrome: a multi-center, double-blind, randomized, placebo-controlled study. Circulation 114 (2006) 48-54
52. Tracleer. web site (2008). http://www.rxlist.com/tracleer-drug.htm
53. Beghetti M., Hoeper M.M., Kiely D.G., et al. Safety experience with bosentan in 146 children 2-11 years with pulmonary arterial hypertension: results from the European post-marketing surveillance program. Pediatr Res 64 (2008) 200-204
54. Krishnan U., Krishnan S., and Gewitz M. Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies. Pediatr Cardiol (2008) [Electronic publication]
55. Goissen C., Ghyselen L., Tourneux P., Krim G., et al. Persistent pulmonary hypertension of the newborn with transposition of the great arteries: successful treatment with bosentan. Eur J Pediatr 167 (2008) 437-440
56. Dunbar D., Doran A., Claussen L., Bingaman D., and Yetman A. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol 93 (2004). http://www.mdconsult.com/das/article/body/110782929-2/jorg=journal& source=&sp=14582946&sid=0/N/409659/1.html?issn=00029149
57. Meyers J.L. Pulmonary hypertension, Eisenmenger syndrome (2007). http://www.emedicine.com/ped/TOPIC2528.htm
58. Iloprost (Ventavis®) package insert.
59. Ivy D. Studies of inhaled iloprost in children with pulmonary hypertension. CHEST 2006: 72nd Annual International Scientific Assembly of the American College of Chest Physicians. October 21-26 (2006)
60. Tweddell J.S. Aspirin: a treatment for the headache of shunt-dependent pulmonary blood flow and parallel circulation?. Circulation 116 (2007) 236-237
61. Li J.S., Yow E., Berezny K.Y., et al. Clinical outcomes of palliative surreys including a systemic-to-pulmonary artery shunt in infants with cyanotic congenital heart disease-does aspirin make a difference?. Circulation 116 (2007) 293-297
62. Vitiello R., McCrindle B.W., Nykanen D., Freedom R.M., and Benson L.N. Complications associated with pediatrics cardiac catheterization. J Am Coll Cardiol 32 (1998) 1433-1440
63. Segel G.B., and Francis C.W. Anticoagulant proteins in childhood venous and arterial thrombosis: a review. Blood Cell Mol Dis 26 (2000) 540-560
64. Fenton K.N., Keiwers R.D., Rebovich B., and Pigula F.A. Interim mortality in infants with systemic to pulmonary artery shunts. Ann Thorac Surg 76 (2003) 152-157
65. Motz W., Wessel A., Ruschewski W., and Bürsch J. Reduced frequency of occlusion of aorto-pulmonary shunts in infants receiving aspirin. Cardiol Young 9 (1999) 474-477
66. Li J.S., Yow E., Berenzy K.Y., et al. Doping of clopidogrel for platelet inhibition in infants and children. Primary results of the platelet inhibition in children on clopidogrel (PICOLO) trial. Circulation 117 (2008) 553-559
67. Maltz L.A., Gauvreau K., Connor J.A., and Jenkins K.J. Clopidogel in a pediatric population: prescribing practice and outcomes from a single center. Pediatr Cardiol (2008) [Electronic publication]
68. Berkenbosch J., Wankum P., and Tobias J. Prospective evaluation of dexmedetomidine for noninvasive procedural sedation in children. Pediatr Crit Care Med 6 (2005)
69. Buck M., and Wilson D. Use of Dexmedetomidine in the pediatric intensive care unit. Pharmacotherapy 28 (2008) 51-57
70. Gillis J.C., and Brogden R.N. Ketorolac: a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs 53 (1997) 139-188
71. Hardman J.G., et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics. Ketorolac tromethamine injection [package insert] (1997), Abbott Laboratories, Inc., North Chicago (Ill)
72. Buck M.L. Clinical experience with ketorolac in children. Ann Pharmacother 28 (1994) 1009-1013
73. Moffett B.S., Wann T.I., Carberry K.E., and Mott A.R. Safety of ketorolac in neonates and infants after cardiac surgery. Paediatr Anaesth 16 (2006) 424-428
74. Torres M, et al. Tenth annual update on pediatric cardiovascular disease. Continuous local anesthetic infusion improves pain control in children after median sternotomy [Research abstract].
75. Rusconi P, Gómez-Marín O, Rossique-González M, et al. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. The Journal of Heart and Lung Transplantation 23:832-838.